

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>JPMORGAN CHASE & CO</u> <hr/> (Last) (First) (Middle) <u>270 PARK AVENUE</u> <hr/> (Street) <u>NEW YORK NY</u> <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>01/25/2018</u>	3. Issuer Name and Ticker or Trading Symbol <u>Solid Biosciences, LLC [SLDB]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,031,601	I	See Footnote ⁽¹⁾⁽²⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				

1. Name and Address of Reporting Person* <u>JPMORGAN CHASE & CO</u> <hr/> (Last) (First) (Middle) <u>270 PARK AVENUE</u> <hr/> (Street) <u>NEW YORK NY</u> <hr/> (City) (State) (Zip)		
---	--	--

1. Name and Address of Reporting Person* <u>JPMC Strategic Investments II Corp</u> <hr/> (Last) (First) (Middle) <u>270 PARK AVENUE</u> <hr/> (Street) <u>NEW YORK NY 10017</u> <hr/> (City) (State) (Zip)		
--	--	--

Explanation of Responses:

- JPMC Strategic Investments II Corporation is the record holder of 3,031,601 shares of Common Stock. JPMC Strategic Investments II Corporation is a wholly-owned subsidiary of JPMorgan Chase & Co., a publicly traded entity listed on the New York Stock Exchange.
- Upon the consummation of the initial public offering of Solid Biosciences Inc., the reporting persons will own less than 10% of the outstanding shares of Common Stock of Solid Biosciences.

Remarks:

JPMorgan Chase & Co., By:
/s/ Michael Lees, Executive 01/25/2018
Director

JPMC Strategic Investments II
Corporation, By: /s/ Ana 01/25/2018
Capella Gomez-Acebo,
Managing Director

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.